Abstract
Get full access to this article
View all access options for this article.
References
1.
Directive 2001/83/EC, as amended
2.
Guideline on similar biological medicinal products (CHMP/437/04)
3.
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (EMEA/CHMP/BWP/49348/2005)
4.
Guideline on production and quality control of monoclonal antibodies and related substances (CHMP/BWP/157653/07)
5.
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CPMP/42832/05)
6.
Note for guidance on non-clinical local tolerance testing of medicinal products (CPMP/SWP/2145/00).
7.
Note for guidance on repeated dose toxicity (CPMP/SWP/1042/99)
8.
Note for guidance for toxicokinetics: A guidance for assessing systemic exposure in toxicological studies (CPMP/ICH/384/95)
9.
Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins (CHMP/EWP/89249/2004)
10.
Guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95/Rev.3/Corr.2)
11.
ICH E10 Choice of Control Group in Clinical Trials CPMP/ICH/364/96
12.
Guideline on the choice of a non-inferiority margin CPMP/EWP/2158/99
13.
Extrapolation of results from clinical studies conducted outside Europe to the EU-population CHMP/EWP/692702/08
14.
Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (CHMP/BMWP/14327/06)
15.
Guideline on risk management systems for medicinal products for human use (EMEA/CHMP96286/2005)
16.
Note for Guidance on Good Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95)
17.
ICH Note for /guidance on Planning Pharmacovigilance Activities (CPMP/ICH/5716/03)